Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of ...

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...

Ocugen (NasdaqCM:OCGN) just gave investors something to talk about by announcing a new licensing agreement that hands Kwangdong Pharmaceutical the exclusive rights to commercialize its gene therapy ...

New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation ...

Sangamo Therapeutics hasn’t convinced a pharma company to buy its experimental gene therapy for Fabry disease after two years ...

In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable ...

Academic, industry, and FDA collaboration is key to personalized treatment manufacturing, says Aldevron’s Max Sellman at BPI this week.

Researchers in Berlin have used base editing to repair mutations that cause the kidney disorder ADPKD in cells from both mice ...